Epidemiological behavior of osteosarcoma during the years 2005-2014 in Mexico
Article Sidebar
Main Article Content
Abstract
Introduction: Osteosarcoma represents 15% of bone neoplasms. In Mexico, it accounts for 4.5% of neoplasms and 46.6% to 74% of malignant bone tumors with a slight predominance of teenage males, and between 50% to 80% knee and proximal humerus.Aim: Identify the distribution, relative frequency and tendency of OS and its projection to five years.Material and methods: Epidemiologic study of a patient database with histological diagnosis of OS from 2005 to 2014. Age, gender, diagnosis, location, side and stage with descriptive statistics and dispersion (ds) were analyzed. Results were measured with Pearson’s index and lineal regression analysis by least squares method.Results: 4,744 cases were analyzed. OS had a frequency of 3.29% and it stood for 56.2% of primary malignant bone tumors. Age was 18.6±16.8 years old with more incidence in the second decade of life (54.1%); men to women ratio was 1.64:1. 55.8% occurred in the knee, followed by proximal humerus (7.1%). Predominant histologic subtype was osteoblastic (76.9%). IIB stage was more frequent (77.6%), followed by IIIB (13.8%). To five years, it predicts an increased incidence of OS.Conclusions: This is the largest case series of OS in Latin America. A rising in OS incidence is predicted. It is necessary to identify risk factors to establish this particular behavior.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
Rodriguez Franco, J. H., Tecualt Gomez, R., Amaya Zepeda, R. A., Atencio Chan, A., Cario Mendez, A. G., & González Valladares, R. (2016). Epidemiological behavior of osteosarcoma during the years 2005-2014 in Mexico. Revista De La Asociación Argentina De Ortopedia Y Traumatología, 81(3), 219-226. https://doi.org/10.15417/542
Issue
Section
Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Manuscript acceptance by the Journal implies the simultaneous non-submission to any other journal or publishing house. The RAAOT is under the Licencia Creative Commnos Atribución-NoComercial-Compartir Obras Derivadas Igual 4.0 Internacional (CC-BY-NC.SA 4.0) (http://creativecommons.org/licences/by-nc-sa/4.0/deed.es). Articles can be shared, copied, distributed, modified, altered, transformed into a derivative work, executed and publicly communicated, provided a) the authors and the original publication (Journal, Publisher and URL) are mentioned, b) they are not used for commercial purposes, c) the same terms of the license are maintained.
In the event that the manuscript is approved for its next publication, the authors retain the copyright and will assign to the journal the rights of publication, edition, reproduction, distribution, exhibition and communication at a national and international level in the different databases. data, repositories and portals.
It is hereby stated that the mentioned manuscript has not been published and that it is not being printed in any other national or foreign journal.
The authors hereby accept the necessary modifications, suggested by the reviewers, in order to adapt the manuscript to the style and publication rules of this Journal.
References
1. Perfil Epidemiológico del Cáncer en Niños y Adolescentes en México. SNAVE. 1-159
2. Rivera-Luna et al. Descriptive Epidemiology in Mexican children with cancer under an open national public health insurance program. BMC Cancer 2014, 14:790: 1-8
3. Burningham Z, Hashibe M, Spector L, Schiffman JD. The Epidemiologý of Sarcoma. Clinical Sarcoma Research 2012, 2; 14: 1-16
4. Eyre R, et al. The epidemiology of bone cancer in 0-39 year olds in northern England, 1981-2002. BMC Cancer 2010, 10;357: 1-7
5. Amaya-Zepeda RA, Espinosa-Aguilar A, Tecualt-Gómez R, Sandoval-Mex AM. GUÍA DE PRÁCTICA CLÍNICA GPC. Diagnóstico Oportuno de OSTEOSARCOMA En Niños y Adolescentes En Primer Y Segundo Nivel de Atención Médica. 2013. 1-52
6. Bielack SD, Jost CL. On behalf ofthe ESMO Guidelines Working Group. Clinical Recommendations. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2008: 19 (Supplement 2): ii94-6
7. Bielack SD, Carrie D, Casali PG. Clinical Recommendations. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Annals of Oncology 2009; 20 (Supplement 4): ii137-9
8. Hogendoon PCW. On behalf of the ESMO/EUROBONET Working Group. Clinical Practice Guidelines. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21 (Supplement 5): vv204-13
9. The ESMO Euroean sarcoma Network Working group. Clinical Practice Guidelines. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012; 23 (Supplement 7): v100-9.
10. Cortés-Rodríguez R, Castañeda-Pichardo G, Tercero-Quintanilla G. Guía de diagnóstico y tratamiento para pacientes pediátricos con osteosarcoma. Archivos de Investigación Materno Infantil. 2010; 2(II):60-6
11. Mejía AJM, Flores AH. Edad de aparición de los diferentes tumores malignos en la infancia. En: Fajardo GA. Cáncer en el niño. Epidemiología descriptiva. Ediciones Cuéllar. México 2002: 289-310.
12. Uribe Rosales DD, Carranza-Arellano C, Ramos-Moreno R. Apectos biológicos y clínicos para comprender mejor al osteosarcoma. Investigación en discapacidad 2014;3(1): 33-40
13. Cuevas-Urióstegui ML, Villasis-Keever MA, Fajardo-Gutiérrez A. Epidemiología del cáncer en adolescentes. Salud Pública de México. 2003; 45: 115-123.
14. Baena-Ocampo LC, Ramírez-Pérez E, Linares-González LM, Delgado-Chávez R. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol. 2009; 13: 16-21.
15. Fajardo-Gutierrez A. Epidemiología descriptiva del cáncer en el niño. México: Unidad de Investigación Médica en Epidemiología Clínica. Hospital de Pediatría Centro Médico Nacional Siglo XXI, IMSS 2000; 43:61-151.
16. Neyssa M, Gebhardt M. Biology and Therapeutic advances for pediatric osteosarcoma. The Oncologist. 2004; 9:422-41
17. Hartford CM, Wodowski KS, Rao BN, Khoury JD, Neel MD, Daw NC: Osteosarcoma among children aged 5 years or younger. J Pediatr Hematol Oncol. 2006; 28 (1):43-7
18. Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M: Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol 2005; 27: 42-5
19. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clinical orthopaedics and Related Research 2002; 397:63-71
20. Pierz KA, Womer RB, Dormans JP. Pediatric bone tumors: Osteosarcoma, Ewing´s Sarcoma, and Chondrosarecoma associated with Multiple Hereditary Osteochondromatosis. Journal of Pediatric Orthopaedics. 2001; 21: 412-8.
21. Picci P. Osteosarcoma (Osteogenic sarcoma) Review. Orphanet Journal of Rare Diseases. 2007; 2 (6):1-4
22. Herzog CE: Overview of sarcomas in the adolescents and young adult population. J Pediatr Hematol Oncol. 2005: 27 (4):215-8
23. Wang F, Allen L, Fung E, Chan CC, Chan CS, Griffith JF. Bone scintigraphy in common tumors with osteolytic components. Clinical Nuclear Medicine 2005; 30 (10) 655-70
24. Fuchs B, Pritchard DJ. Ethiology of osteosarcomas. Clinical Orthopaedics and Related Research. 2002; 397:40-52.
25. Unni KK, et al. Tumors of the Bones and Joints. AFIP ATLAS OF TUMOR PATHOLOGY. ARP. 2005:135-184
26. Unni KK, et al. Osteosarcoma en: Dahlin´s Bone Tumors. Lippincot Williams & Wilkins. 2010: 122-156.
27. Bollough PG. Ostesarcoma en: Orthopaedic Pathology. Mosby ELSEVIER. 2010, 5th Ed. 376-385
28. Mirabello L, Troisi R, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 2009; 7: 1531-43
29. Savage A, Mirabello A. Epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011; 2011:1-13
30. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152: 3-13
31. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma and Ewing´s sarcoma, national data base report. Clinical Orthopaedics and Related Research. 2007; 459:40-7
32. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar KG, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. American family Physician 2002; 65 (6): 1123-32.
33. Cade S. Osteogenic Sarcoma. A Study Based on 133 Patients. Clinical Orthopaedics and Related Research 2005; 438:15-8
34. Bielack S 2008, Hagendoon PCW 2010. The ESMO/European sarcoma Network Working Group 2012.
35. Fletcher C, Bridge J, Hogendoorn P, Mertens F. WHO Classification of Tumors of Soft Tissue and Bone. IARC. 2013: 282-295
2. Rivera-Luna et al. Descriptive Epidemiology in Mexican children with cancer under an open national public health insurance program. BMC Cancer 2014, 14:790: 1-8
3. Burningham Z, Hashibe M, Spector L, Schiffman JD. The Epidemiologý of Sarcoma. Clinical Sarcoma Research 2012, 2; 14: 1-16
4. Eyre R, et al. The epidemiology of bone cancer in 0-39 year olds in northern England, 1981-2002. BMC Cancer 2010, 10;357: 1-7
5. Amaya-Zepeda RA, Espinosa-Aguilar A, Tecualt-Gómez R, Sandoval-Mex AM. GUÍA DE PRÁCTICA CLÍNICA GPC. Diagnóstico Oportuno de OSTEOSARCOMA En Niños y Adolescentes En Primer Y Segundo Nivel de Atención Médica. 2013. 1-52
6. Bielack SD, Jost CL. On behalf ofthe ESMO Guidelines Working Group. Clinical Recommendations. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2008: 19 (Supplement 2): ii94-6
7. Bielack SD, Carrie D, Casali PG. Clinical Recommendations. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Annals of Oncology 2009; 20 (Supplement 4): ii137-9
8. Hogendoon PCW. On behalf of the ESMO/EUROBONET Working Group. Clinical Practice Guidelines. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21 (Supplement 5): vv204-13
9. The ESMO Euroean sarcoma Network Working group. Clinical Practice Guidelines. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012; 23 (Supplement 7): v100-9.
10. Cortés-Rodríguez R, Castañeda-Pichardo G, Tercero-Quintanilla G. Guía de diagnóstico y tratamiento para pacientes pediátricos con osteosarcoma. Archivos de Investigación Materno Infantil. 2010; 2(II):60-6
11. Mejía AJM, Flores AH. Edad de aparición de los diferentes tumores malignos en la infancia. En: Fajardo GA. Cáncer en el niño. Epidemiología descriptiva. Ediciones Cuéllar. México 2002: 289-310.
12. Uribe Rosales DD, Carranza-Arellano C, Ramos-Moreno R. Apectos biológicos y clínicos para comprender mejor al osteosarcoma. Investigación en discapacidad 2014;3(1): 33-40
13. Cuevas-Urióstegui ML, Villasis-Keever MA, Fajardo-Gutiérrez A. Epidemiología del cáncer en adolescentes. Salud Pública de México. 2003; 45: 115-123.
14. Baena-Ocampo LC, Ramírez-Pérez E, Linares-González LM, Delgado-Chávez R. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol. 2009; 13: 16-21.
15. Fajardo-Gutierrez A. Epidemiología descriptiva del cáncer en el niño. México: Unidad de Investigación Médica en Epidemiología Clínica. Hospital de Pediatría Centro Médico Nacional Siglo XXI, IMSS 2000; 43:61-151.
16. Neyssa M, Gebhardt M. Biology and Therapeutic advances for pediatric osteosarcoma. The Oncologist. 2004; 9:422-41
17. Hartford CM, Wodowski KS, Rao BN, Khoury JD, Neel MD, Daw NC: Osteosarcoma among children aged 5 years or younger. J Pediatr Hematol Oncol. 2006; 28 (1):43-7
18. Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M: Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol 2005; 27: 42-5
19. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clinical orthopaedics and Related Research 2002; 397:63-71
20. Pierz KA, Womer RB, Dormans JP. Pediatric bone tumors: Osteosarcoma, Ewing´s Sarcoma, and Chondrosarecoma associated with Multiple Hereditary Osteochondromatosis. Journal of Pediatric Orthopaedics. 2001; 21: 412-8.
21. Picci P. Osteosarcoma (Osteogenic sarcoma) Review. Orphanet Journal of Rare Diseases. 2007; 2 (6):1-4
22. Herzog CE: Overview of sarcomas in the adolescents and young adult population. J Pediatr Hematol Oncol. 2005: 27 (4):215-8
23. Wang F, Allen L, Fung E, Chan CC, Chan CS, Griffith JF. Bone scintigraphy in common tumors with osteolytic components. Clinical Nuclear Medicine 2005; 30 (10) 655-70
24. Fuchs B, Pritchard DJ. Ethiology of osteosarcomas. Clinical Orthopaedics and Related Research. 2002; 397:40-52.
25. Unni KK, et al. Tumors of the Bones and Joints. AFIP ATLAS OF TUMOR PATHOLOGY. ARP. 2005:135-184
26. Unni KK, et al. Osteosarcoma en: Dahlin´s Bone Tumors. Lippincot Williams & Wilkins. 2010: 122-156.
27. Bollough PG. Ostesarcoma en: Orthopaedic Pathology. Mosby ELSEVIER. 2010, 5th Ed. 376-385
28. Mirabello L, Troisi R, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 2009; 7: 1531-43
29. Savage A, Mirabello A. Epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011; 2011:1-13
30. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009; 152: 3-13
31. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma and Ewing´s sarcoma, national data base report. Clinical Orthopaedics and Related Research. 2007; 459:40-7
32. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar KG, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. American family Physician 2002; 65 (6): 1123-32.
33. Cade S. Osteogenic Sarcoma. A Study Based on 133 Patients. Clinical Orthopaedics and Related Research 2005; 438:15-8
34. Bielack S 2008, Hagendoon PCW 2010. The ESMO/European sarcoma Network Working Group 2012.
35. Fletcher C, Bridge J, Hogendoorn P, Mertens F. WHO Classification of Tumors of Soft Tissue and Bone. IARC. 2013: 282-295